Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 6/20 | 0.58 |
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.46 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.43 |
| ▸ | SCD | O00767 | 1/20 | 0.42 |
| ▸ | TRPM8 | Q7Z2W7 | 4/20 | 0.42 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13676301 | 0.96 | IDO1 (0.55) | IDO1GPR119ABCB1KMT2AHRH3 | |
| SCHEMBL23928887 | 0.88 | IDO1 (0.47) | IDO1GPR119ABCB1HRH3SCD | |
| SCHEMBL1223646 | 0.87 | IDO1 (0.56) | IDO1GPR119KMT2AHRH3 | |
| SCHEMBL2346324 | 0.86 | IDO1 (0.47) | IDO1GPR119KMT2AHRH3 | |
| SCHEMBL12481590 | 0.86 | IDO1 (0.56) | IDO1GPR119KMT2AHRH3 | |
| SCHEMBL1690860 | 0.86 | IDO1 (0.47) | IDO1GPR119HRH3SCDTRPM8 | |
| SCHEMBL31236009 | 0.86 | IDO1 (0.54) | IDO1GPR119HRH3 | |
| SCHEMBL1691354 | 0.85 | TRPM8 (0.59) | IDO1GPR119TRPM8TRPV1 | |
| SCHEMBL12481544 | 0.85 | IDO1 (0.57) | IDO1GPR119ABCB1KMT2AHRH3 | |
| SCHEMBL12491393 | 0.85 | IDO1 (0.57) | IDO1GPR119HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10385070-B2 | Chroman-spirocyclic piperidine amides as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2019-08-20 | — | — | US | disclosed |
| US-10385070-B2 | Chroman-spirocyclic piperidine amides as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2019-08-20 | — | — | US | disclosed |
| EP-2675812-B1 | CHROMAN - SPIROCYCLIC PIPERIDINE AMIDES AS MODULATORS OF ION CHANNELS | VERTEX PHARMA (US) | 2017-08-30 | — | — | EP | disclosed |
| EP-2675812-B1 | CHROMAN - SPIROCYCLIC PIPERIDINE AMIDES AS MODULATORS OF ION CHANNELS | VERTEX PHARMA (US) | 2017-08-30 | — | — | EP | disclosed |
| WO-2017124657-A1 | BRUTON'S TYROSINE KINASE INHIBITOR HAVING SPIRAL OR BRIDGED RING STRUCTURE AND PREPARATION METHOD THEREOF | 成都倍特药业有限公司 | 2017-07-27 | — | — | WO | disclosed |
| US-9168248-B2 | Spiro compounds useful as inhibitors of stearoyl-coenzyme A delta-9 desaturase | MERCK CANADA INC. (CA) | 2015-10-27 | — | — | US | disclosed |
| EP-2398809-B1 | NOVEL SPIRO COMPOUNDS USEFUL AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE | MERCK CANADA INC (CA) | 2015-07-08 | — | — | EP | disclosed |
| EP-2675812-A1 | CHROMAN - SPIROCYCLIC PIPERIDINE AMIDES AS MODULATORS OF ION CHANNELS | Vertex Pharmaceuticals Incorporated (US) | 2013-12-25 | — | — | EP | disclosed |
| US-20120245136-A1 | CHROMAN-SPIROCYCLIC PIPERIDINE AMIDES AS MODULATORS OF ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED | 2012-09-27 | — | — | US | disclosed |
| US-20120245136-A1 | CHROMAN-SPIROCYCLIC PIPERIDINE AMIDES AS MODULATORS OF ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED | 2012-09-27 | — | — | US | disclosed |
| US-20120245136-A1 | CHROMAN-SPIROCYCLIC PIPERIDINE AMIDES AS MODULATORS OF ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED | 2012-09-27 | — | — | US | disclosed |
| WO-2012112743-A1 | CHROMAN - SPIROCYCLIC PIPERIDINE AMIDES AS MODULATORS OF ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-08-23 | — | — | WO | disclosed |
| US-20110312952-A1 | NOVEL SPIRO COMPOUNDS USEFUL AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE | MERCK CANADA INC. | 2011-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110312952-A1 | NOVEL SPIRO COMPOUNDS USEFUL AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE | SCD, SCD5, SREBF1 | IDO1 1403/4885GPR119 51/4885ABCB1 1800/4885 |
| US-20120245136-A1 | CHROMAN-SPIROCYCLIC PIPERIDINE AMIDES AS MODULATORS OF ION CHANNELS | KCNJ2, KCNJ1, KCNC1 | IDO1 3309/4885GPR119 662/4885ABCB1 819/4885 |
| US-10385070-B2 | Chroman-spirocyclic piperidine amides as modulators of ion channels | KCNJ2, KCNJ1, KCNC1 | IDO1 3309/4885GPR119 662/4885ABCB1 819/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.